HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kensei Tobinai Selected Research

Cyclophosphamide (Cytoxan)

5/2024Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
10/2022Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
3/2021A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
1/2021Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
1/2021A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.
12/2020Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.
1/2019Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
11/2018Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
10/2018Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
1/2018Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kensei Tobinai Research Topics

Disease

57Lymphoma (Lymphomas)
10/2022 - 01/2002
53Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2023 - 12/2002
47Neoplasms (Cancer)
04/2023 - 01/2002
30B-Cell Lymphoma (Lymphoma, B Cell)
05/2024 - 01/2002
24Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
05/2024 - 05/2004
23Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
03/2024 - 03/2010
21Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2024 - 08/2003
19Multiple Myeloma
12/2021 - 10/2007
18Infections
11/2019 - 03/2002
17Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
06/2021 - 12/2002
16Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
08/2022 - 02/2003
14Hodgkin Disease (Hodgkin's Disease)
03/2024 - 02/2003
13Disease Progression
05/2024 - 02/2003
12Neutropenia
01/2018 - 02/2002
11T-Cell Lymphoma (Lymphoma, T Cell)
01/2023 - 12/2002
9Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
01/2023 - 05/2011
8Pneumonia (Pneumonitis)
12/2021 - 02/2003
8B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
03/2021 - 01/2009
8Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2018 - 06/2003
8Thrombocytopenia (Thrombopenia)
10/2016 - 12/2007
7Lymphopenia (Lymphocytopenia)
06/2021 - 03/2015
7Hematologic Neoplasms (Hematological Malignancy)
11/2016 - 04/2002
6Graft vs Host Disease (Graft-Versus-Host Disease)
10/2017 - 03/2002
6Anemia
01/2016 - 10/2006
5Fever (Fevers)
06/2021 - 11/2008
4Hepatitis
03/2024 - 12/2014
4Myelodysplastic Syndromes (Myelodysplastic Syndrome)
04/2017 - 08/2007
4Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2016 - 09/2007
3Mycosis Fungoides
03/2024 - 10/2004
3Hypertension (High Blood Pressure)
01/2024 - 03/2016
3Diarrhea
12/2020 - 10/2004
3Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
07/2019 - 07/2004
3Exanthema (Rash)
03/2018 - 01/2016
3Fatigue
03/2018 - 10/2006
3Sepsis (Septicemia)
01/2018 - 02/2003
3Leukopenia
12/2016 - 11/2010
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2011 - 07/2007
3Leukemia
09/2010 - 04/2002
2Hypoalbuminemia
06/2021 - 03/2018

Drug/Important Bio-Agent (IBA)

55Rituximab (Mabthera)FDA Link
05/2024 - 01/2002
24Vincristine (Oncovin)FDA LinkGeneric
05/2024 - 02/2003
23Doxorubicin (Adriamycin)FDA LinkGeneric
05/2024 - 02/2003
23Cyclophosphamide (Cytoxan)FDA LinkGeneric
05/2024 - 08/2003
22Monoclonal AntibodiesIBA
10/2020 - 01/2002
14Prednisolone (Predate)FDA LinkGeneric
01/2021 - 02/2003
12mogamulizumabIBA
08/2022 - 03/2010
11Prednisone (Sone)FDA LinkGeneric
05/2024 - 06/2005
11Bortezomib (Velcade)FDA Link
12/2021 - 06/2007
9Dexamethasone (Maxidex)FDA LinkGeneric
06/2021 - 04/2011
9Bendamustine HydrochlorideFDA Link
10/2018 - 09/2010
8Brentuximab VedotinIBA
04/2021 - 07/2014
7CladribineFDA LinkGeneric
07/2009 - 04/2002
6obinutuzumabIBA
10/2019 - 01/2013
6CCR4 ReceptorsIBA
05/2019 - 03/2012
6Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2018 - 02/2002
510-propargyl-10-deazaaminopterinFDA Link
03/2024 - 04/2010
5Biomarkers (Surrogate Marker)IBA
03/2023 - 05/2008
5Histone Deacetylase InhibitorsIBA
01/2023 - 01/2010
5Etoposide (VP 16)FDA LinkGeneric
12/2020 - 02/2003
5Lenalidomide (CC 5013)FDA Link
11/2020 - 03/2016
5Immunoconjugates (Immunoconjugate)IBA
09/2020 - 09/2002
5AntibodiesIBA
09/2020 - 08/2003
5VorinostatFDA Link
01/2018 - 01/2010
4NivolumabIBA
03/2024 - 03/2017
4Agammaglobulinaemia Tyrosine KinaseIBA
04/2023 - 01/2016
4Anaplastic Lymphoma KinaseIBA
01/2023 - 07/2012
4Transaminases (Aminotransferases)IBA
06/2021 - 11/2010
4ibrutinibIBA
06/2021 - 01/2016
4Adenosine Monophosphate (AMP)IBA
12/2020 - 12/2007
4DNA (Deoxyribonucleic Acid)IBA
10/2019 - 05/2004
4carfilzomibIBA
09/2019 - 03/2016
4forodesineIBA
01/2019 - 07/2012
4Proteins (Proteins, Gene)FDA Link
02/2018 - 02/2005
4Inotuzumab OzogamicinIBA
01/2018 - 08/2010
4CalicheamicinsIBA
10/2016 - 05/2009
3darinaparsinIBA
12/2023 - 02/2021
3pomalidomideIBA
06/2021 - 01/2015
3fludarabineIBA
03/2021 - 07/2004
3GalliumIBA
10/2019 - 10/2018
3Anti-Bacterial Agents (Antibiotics)IBA
07/2019 - 08/2010
3Alanine Transaminase (SGPT)IBA
03/2018 - 10/2004
3Melphalan (Alkeran)FDA LinkGeneric
01/2016 - 04/2011
3Proteasome InhibitorsIBA
01/2008 - 06/2007
3ibritumomab tiuxetan (Zevalin)FDA Link
01/2007 - 10/2002
2tirabrutinibIBA
04/2023 - 05/2019
2axicabtagene ciloleucelIBA
03/2023 - 01/2022
2Histone Deacetylases (Histone Deacetylase)IBA
09/2022 - 10/2012
2Cyclin D1IBA
06/2021 - 01/2002
2pembrolizumabIBA
06/2021 - 11/2020

Therapy/Procedure

58Therapeutics
11/2023 - 03/2002
51Drug Therapy (Chemotherapy)
03/2024 - 12/2002
14Hematopoietic Stem Cell Transplantation
03/2024 - 07/2006
14Stem Cell Transplantation
10/2020 - 04/2002
8Radioimmunotherapy
01/2009 - 10/2002
7Transplantation
01/2018 - 07/2002
5Radiotherapy
02/2021 - 06/2005
5Chemoradiotherapy
01/2018 - 02/2006
5Combination Drug Therapy (Combination Chemotherapy)
04/2016 - 02/2003
3Cell Transplantation
01/2018 - 08/2007
3Homologous Transplantation
01/2018 - 04/2002